N-[4-(3,5-difluorophenyl)-1,3-thiazol-2-yl]-2-(2,5,7-trimethyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide | 1246275-66-0

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: N-[4-(3,5-difluorophenyl)-1,3-thiazol-2-yl]-2-(2,5,7-trimethyl-4,6-dioxo-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-d]pyrimidin-3-yl)acetamide
• 英文别名: N-[4-(3,5-difluorophenyl)-1,3-thiazol-2-yl]-2-(2,5,7-trimethyl-4,6-dioxopyrazolo[3,4-d]pyrimidin-3-yl)acetamide
• CAS: 1246275-66-0
• 化学式: C₁₉H₁₆F₂N₆O₃S
• 分子量: 446.437
• InChiKey: WJLJDJCOOKTDPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  129
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPAI MODULATORS
  申请人：Chaudhari Sachin Sundarlal

  公开号：US20120041004A1

  公开（公告）日：2012-02-16

  The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

  本发明涉及化合物公式(I)的新型融合嘧啶二酮衍生物，其为TRPA（瞬时受体电位亚家族A）调节剂。特别地，本发明所描述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚家族A，成员1）调节的疾病、状况和/或障碍。本发明还提供了制备所述化合物的方法、用于其合成的中间体、其制药组合物以及用于治疗或预防由TRPA1调节的疾病、状况和/或障碍的方法。
• FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS
  申请人：Glenmark Pharmaceuticals, S.A.

  公开号：US20140128603A1

  公开（公告）日：2014-05-08

  The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.

  本发明涉及式（I）的新型融合嘧啶二酮衍生物，其为TRPA（瞬时受体电位亚家族A）调节剂。特别地，本发明所描述的化合物可用于治疗或预防由TRPA1（瞬时受体电位亚家族A，成员1）调节的疾病、状况和/或紊乱。本发明还提供了制备所述化合物的方法、用于其合成的中间体、其药物组成物以及用于治疗或预防由TRPA1调节的疾病、状况和/或紊乱的方法。
• Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators
  申请人：Glenmark Pharmaceuticals S.A.

  公开号：EP2708538A1

  公开（公告）日：2014-03-19

  The present invention relates to a process for preparing a compound of formula (Id-1) or a pharmaceutically acceptable salt thereof, which comprises reacting a compound of formula (35) with amine compound of formula (18) wherein, R1 and R2, which may be same or different, are independently selected from hydrogen and substituted or unsubstituted alkyl; U is substituted or unsubstituted heterocycles selected from thiazole and isoxazole; and V is substituted or unsubstituted aryl.

  本发明涉及一种制备式（Id-1）化合物的工艺 或其药学上可接受的盐的工艺，该工艺包括 使式（35）化合物与式（18）胺化合物反应 其中 R1 和 R2（可以相同或不同）独立地选自氢和取代或未取代的烷基； U 是取代或未取代的杂环，选自噻唑和异噁唑；以及 V 是取代或未取代的芳基。
• US8623880B2
  申请人：——

  公开号：US8623880B2

  公开（公告）日：2014-01-07
• US9000159B2
  申请人：——

  公开号：US9000159B2

  公开（公告）日：2015-04-07